市場調查報告書

到持續性表皮缺損(PED):至2030年的市場分析,流行病學,預測

Persistent Epithelial Defects (PEDs)- Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968103
出版日期 內容資訊 英文 131 Pages
商品交期: 最快1-2個工作天內
價格
到持續性表皮缺損(PED):至2030年的市場分析,流行病學,預測 Persistent Epithelial Defects (PEDs)- Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年10月30日內容資訊: 英文 131 Pages
簡介

本報告提供美國,德國,法國,義大利,西班牙,英國,日本的主要7個國家的持續性表皮缺損(PED)的流行病學相關市場調查,疾病概要,流行病學與患者數,目前治療方法,未滿足需求,新的治療方法,各國市場分析與展望,促進市場成長的要素及阻礙因素,案例研究等資訊。

目錄

第1章 主要調查結果

第2章 市場概要

第3章 摘要整理

第4章 組織

第5章 流行病學與市場調查手法

第6章 疾病概要

  • 簡介
  • 臨床表現
  • 病因
  • 病理學
  • 診斷
    • 鑑別診斷

第7章 流行病學和患者數

    • 主要調查結果
  • 的新病例數主要7個國家

第8章 主要7個國家的流行病學

  • 前提和根據
  • 美國
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第9章 目前治療方法

第10章 未滿足需求

第11章 上市的治療藥

  • OXERVATE:Dompe Farmaceutici
    • 概要
    • 藥事法規方面的里程碑
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介

第12章 新治療方法

  • 主要的競爭產品
  • Nexagon:OcuNexus Therapeutics/Eyevance Pharmaceuticals
    • 概要
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • ST266:Noveome Biotherapeutics
    • 概要
  • RGN-259:RegeneRx Biopharmaceuticals
  • REC-0559:Recordati Rare Diseases/Mimetech
  • 其他的治療藥物
    • DE-105:Santen Pharmaceutical

第13章 主要7個國家的市場分析

  • 主要調查結果
  • 市場規模

第14章 主要7個國家的市場展望

  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第15章 促進市場成長的要素

第16章 市場障礙

第17章 SWOT分析

第18章 市場進入與償付

第19章 案例研究

第20章 主要專家的見解

第21章 參考文件

第22章 附錄

第23章 DelveInsight的服務內容

第24章 免責聲明

第25章 關於DelveInsight

目錄
Product Code: DIMI0929

DelveInsight's 'Persistent Epithelial Defect (PED) - Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the Persistent Epithelial Defect (PED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Persistent Epithelial Defect (PED) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted PED symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Persistent Epithelial Defect (PED) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Persistent Epithelial Defect (PED) Disease Understanding and Treatment Algorithm

Persistent Epithelial Defect (PED) Overview

Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. PED is defined as "defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses". PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7-14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.

The normal corneal wound healing process can be disrupted from defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and several other etiologies. Such defects are especially common in individuals with metaherpes, neurotrophic keratopathy, or diabetic keratopathy.

Some of the symptoms of PEDs are loss of corneal epithelial cells, delayed epithelialization post-injury, nonhealing epithelial defect and others which can be commonly due to Epithelial/limbal, inflammatory disease, Neurotrophic, mechanical causes, and others. Evaluating a PED involves instillation of fluorescein to monitor the size, location, and depth of the defect. A thorough physical exam should reveal findings such as inflammation in the anterior chamber, eyelid abnormalities, or decreased sensation of the cornea.

Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is important to treat the underlying causative condition, which may include infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. Furthermore, standard treatments, such as bandage contact lenses (BCLs) and artificial tears (ATs), aim to provide barrier protection to the epithelial layers.

Persistent Epithelial Defect (PED) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Persistent Epithelial Defect (PED) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Persistent Epithelial Defect (PED) market report gives a thorough understanding of PED symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PED symptoms of treatment algorithms and treatment guidelines for PED symptoms in the US, Europe, and Japan.

Persistent Epithelial Defect (PED) Epidemiology

The Persistent Epithelial Defect symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Defect (PED) epidemiology segmented as the Total Incident cases of Persistent epithelial defect, Etiology-specific cases of Persistent Epithelial Defect (PED). The report includes the Incident scenario of PED symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Persistent Epithelial Defect (PED) Epidemiology

The epidemiology segment also provides the Persistent Epithelial Defect (PED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total Incident population of Persistent Epithelial Defect (PED) in 7MM countries was estimated to be 238,058 cases in 2017.

Persistent Epithelial Defect (PED) Drug Chapters

The drug chapter segment of the Persistent Epithelial Defect (PED) report encloses the detailed analysis of PED marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Persistent Epithelial Defect (PED) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The therapeutic market size of PED in the US is mainly accounted for treatment options, such as approved therapy i.e Oxervate and off-label therapies such as lubricants, punctal occlusion, bandage contact lens, topical antibiotics, steroids and others. Amniotic membrane grafting, autologous serum, scleral contact lenses, have been recommended for the treatment of refractory cases.

Products detail in the report…

Persistent Epithelial Defect (PED) Emerging Drugs

Nexagon: OcuNexus Therapeutics, Eyevance Pharmaceuticals

It a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43). Targeting the gap junctions may prevent immune system responses that may lead to inflammatory cascade and promote the microvasculature and regeneration of corneal epithelium. Nexagon has a market advantage in the US, as it received orphan drug designation from the FDA. It is being developed by OcuNexus Therapeutics in partnership with Eyevance Pharmaceuticals. Currently, the drug is under phase II studies for PED.

Products detail in the report…

Persistent Epithelial Defect (PED) Market Outlook

The Persistent Epithelial Defect (PED) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Persistent Epithelial Defect (PED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Persistent Epithelial Defect (PED) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Persistent Epithelial Defect (PED) market in 7MM is expected to change in the study period 2017-2030.

The first step in the management of any epithelial abnormality is to determine the etiology of the disease. Currently, "bandage" methods are used to help re-epithelialize a cornea. The current approaches include Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Tetracyclines, prophylactic topical antibiotics and steroids. For the treatment of refractory cases, Amniotic membrane grafting, autologous serum, Scleral contact lenses, and others have recommended. In severe cases, a conjunctival graft may be placed over the cornea.

Key Findings

This section includes a glimpse of the Persistent Epithelial Defect (PED) market in 7MM. The market size of PED in the seven major markets was found to be USD 179.1 million in 2017.

The United States Market Outlook

This section provides the total Persistent Epithelial Defect (PED) market size and market size by therapies in the United States.

The United States accounts for the highest market size of PED in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Aggressive lubrication is typically the first-line therapy with either high-frequency application of preservative-free artificial tears or sterile ophthalmic ointment. This may prove to be particularly difficult with the noncompliant patient. Punctal occlusion may increase epithelial contact time with lubricating tears and ointments, and patients may benefit from temporary or permanent occlusion of the punctual. However, this is not recommended in the circumstances requiring the continued use of toxic agents.

If the response to the previous measures is inadequate or for refractory cases, therapies such as Amniotic membrane grafting, autologous serum are the choice. Autologous serum drops have been reported to be beneficial in the treatment of persistent epithelial defect recalcitrant to conventional therapy.

Along with this, Oxervate - first-ever recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis recently, which is one of the underlying etiologies for PED, thus may help some of the PED patients. Also, Dompe Farmaceutici may have the chance to expand its indication to PED with observed results in the future. It is the first-ever topical biologic medication approved in ophthalmology and has given a boost to a similar type of researches.

EU-5 Countries: Market Outlook

The total Persistent Epithelial Defect (PED) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

if the etiology of the PED is due to the deficiency of the stem cells that are responsible for repopulating the epithelium, then Limbal stem cell transplantation (surgical replacement with stem cell (allo or autografts) is indicated. This is frequently seen in conditions such as ocular cicatricial pemphigoid, Stevens-Johnson syndrome, and severe alkali burns and others. Moreover, Scleral contact lenses, including the prosthetic replacement of the ocular surface ecosystem (PROSE) lens, may be utilized for refractory persistent epithelial defects.

One recent treatment alternative is the topical use of Regenerating Agent Eye Drops (RGTAs). RGTA (OTR4120 (Cacicol20); laboratories Thea,) is a carboxymethyl dextran sulfate polymer bioengineered to replace heparan sulfate, which is an important factor both for matrix proteins and for growth factors. It is available in Europe as a novel therapeutic approach to treat PED patients, that are resistant to conventional therapy.

Japan Market Outlook

The total Persistent Epithelial Defect (PED) market size and market size by therapies in Japan are also mentioned.

Persistent Epithelial Defect (PED) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Persistent Epithelial Defect (PED) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Persistent Epithelial Defect (PED) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Persistent Epithelial Defect (PED) key players involved in developing targeted therapeutics.

Major players include OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneX Biotherapeutics, Recordati Rare Diseases., Mimetech. Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is expected to get launched in the US market by 2022.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Persistent Epithelial Defect (PED) emerging therapies.

Reimbursement Scenario in Persistent Epithelial Defect (PED)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

Payers have established their therapeutic guidelines, manage access more tightly and scrutinize the price of new therapies, meaning pharma companies need to provide the evidence sought by payers, specifical information such as comparative effectiveness, cost-effectiveness and real-world data. Gaining market access in pharma across Europe has always presented challenges to pharmaceutical firms. The region has a common regulator, the European Medicines Agency, and most of its citizens receive healthcare from government-funded, often country-wide, health systems.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Persistent Epithelial Defect (PED) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Persistent Epithelial Defect (PED) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive & Market Intelligence analysis of the Persistent Epithelial Defect (PED) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Persistent Epithelial Defect (PED), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
  • Comprehensive insight has been provided into the Persistent Epithelial Defect (PED) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Persistent Epithelial Defect (PED) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Persistent Epithelial Defect (PED) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Persistent Epithelial Defect (PED) market

Report Highlights:

  • In the coming years, Persistent Epithelial Defect (PED) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Persistent Epithelial Defect (PED) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for PED. Launch of emerging therapies will significantly impact the Persistent Epithelial Defect (PED) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PED.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Persistent Epithelial Defect (PED) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Persistent Epithelial Defect (PED) Pipeline Analysis
  • Persistent Epithelial Defect (PED) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Persistent Epithelial Defect (PED) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Persistent Epithelial Defect (PED) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Persistent Epithelial Defect (PED) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the Persistent Epithelial Defect (PED) Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Persistent Epithelial Defect (PED) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Persistent Epithelial Defect (PED)market Size during the forecast period (2017-2030)?
  • At what CAGR, the Persistent Epithelial Defect (PED) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Persistent Epithelial Defect (PED) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Persistent Epithelial Defect (PED) market growth till 2030 and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Persistent Epithelial Defect (PED)?
  • What is the historical Persistent Epithelial Defect (PED) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What would be the forecasted patient pool of Persistent Epithelial Defect (PED) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Persistent Epithelial Defect (PED)?
  • Out of all 7MM countries, which country would have the highest Incident population of Persistent Epithelial Defect (PED) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Persistent Epithelial Defect (PED)?
  • What are the current treatment guidelines for the treatment of Persistent Epithelial Defect (PED) in the USA, Europe, and Japan?
  • What are the Persistent Epithelial Defect (PED) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Persistent Epithelial Defect (PED)?
  • How many therapies are developed by each company for the treatment of Persistent Epithelial Defect (PED)?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Persistent Epithelial Defect (PED)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Persistent Epithelial Defect (PED) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Persistent Epithelial Defect (PED) and their status?
  • What are the key designations that have been granted for the emerging therapies for Persistent Epithelial Defect (PED)?
  • What are the global historical and forecasted market of Persistent Epithelial Defect (PED)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Persistent Epithelial Defect (PED) market
  • To understand the future market competition in the Persistent Epithelial Defect (PED) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Persistent Epithelial Defect (PED) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Persistent Epithelial Defect (PED) market
  • To understand the future market competition in the Persistent Epithelial Defect (PED) market

Table of Contents

1. Key Insights

2. Persistent Epithelial Defect (PED): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of PED in 2017
  • 2.2. Total Market Share (%) Distribution of PED in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Persistent Epithelial Disease (PED): Disease Overview

  • 6.1. Introduction
  • 6.2. Clinical Presentation
  • 6.3. Etiology
  • 6.4. Pathophysiology
  • 6.5. Diagnosis
    • 6.5.1. Differential diagnosis

7. Epidemiology and Patient Population

    • 7.1.1. Key Findings
  • 7.2. Total Incident cases of Persistent epithelial defect in 7MM

8. 7MM Epidemiology of Persistent Epithelial Defects

  • 8.1. Assumptions and Rationale
  • 8.2. United States
    • 8.2.1. Total Incident cases of Persistent epithelial defect in the United States
    • 8.2.2. Etiology-specific cases of Persistent epithelial defect in the United States
  • 8.3. EU5 Countries
  • 8.4. Germany
    • 8.4.1. Total Incident cases of Persistent epithelial defect in Germany
    • 8.4.2. Etiology-specific cases of Persistent epithelial defect in Germany
  • 8.5. France
    • 8.5.1. Total Incident cases of Persistent epithelial defect in France
    • 8.5.2. Etiology-specific cases of Persistent epithelial defect in France
  • 8.6. Italy
    • 8.6.1. Total Incident cases of Persistent epithelial defect in Italy
    • 8.6.2. Etiology-specific cases of Persistent epithelial defect in Italy
  • 8.7. Spain
    • 8.7.1. Total Incident cases of Persistent epithelial defect in Spain
    • 8.7.2. Etiology-specific cases of Persistent epithelial defect in Spain
  • 8.8. UK
    • 8.8.1. Total Incident cases of Persistent epithelial defect in the United Kingdom
    • 8.8.2. Etiology-specific cases of Persistent epithelial defect in the United Kingdom
  • 8.9. Japan
    • 8.9.1. Total Incident cases of Persistent epithelial defect in Japan
    • 8.9.2. Etiology-specific cases of Persistent epithelial defect in Japan

9. Current Treatment Practices

10. Unmet Needs

11. Marketed Therapies

  • 11.1. OXERVATE: Dompe Farmaceutici
    • 11.1.1. Drug Description
    • 11.1.2. Regulatory Milestones
    • 11.1.3. Other Developmental Activities
    • 11.1.4. Clinical Development
    • 11.1.5. Safety and Efficacy
    • 11.1.6. Product Profile

12. Emerging Therapies

  • 12.1. Key Cross Competition
  • 12.2. Nexagon: OcuNexus Therapeutics/Eyevance Pharmaceuticals
    • 12.2.1. Drug Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile
  • 12.3. ST266: Noveome Biotherapeutics
    • 12.3.1. Product Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Product Profile
  • 12.4. RGN-259: RegeneRx Biopharmaceuticals
    • 12.4.1. Drug Description
    • 12.4.2. Other Developmental Activities
    • 12.4.3. Clinical Development
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Product Profile
  • 12.5. REC-0559: Recordati Rare Diseases/Mimetech
    • 12.5.1. Drug Description
    • 12.5.2. Other Developmental Activities
    • 12.5.3. Clinical Development
    • 12.5.4. Product Profile
  • 12.6. Other therapies
    • 12.6.1. DE-105: Santen Pharmaceutical
    • 12.6.2. Product Profile

13. Persistent Epithelial Disease (PED): 7 Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Market Size of Persistent epithelial defect in 7MM

14. Seven Major Market Outlook

  • 14.1. United States Market Size
    • 14.1.1. Total market size of Persistent epithelial defect in the United States
    • 14.1.2. Market size of Persistent epithelial defect by Therapies in the US
  • 14.2. Germany
    • 14.2.1. Total market size of Persistent epithelial defect in Germany
    • 14.2.2. Market size of Persistent epithelial defect by Therapies in Germany
  • 14.3. France
    • 14.3.1. Total market size of Persistent epithelial defect in France
    • 14.3.2. Market size of Persistent epithelial defect by Therapies in France
  • 14.4. Italy
    • 14.4.1. Total market size of Persistent epithelial defect in Italy
    • 14.4.2. Market size of Persistent epithelial defect by Therapies in Italy
  • 14.5. Spain
    • 14.5.1. Total Market Size of Persistent epithelial defect in Spain
    • 14.5.2. Market size of Persistent epithelial defect by Therapies in Spain
  • 14.6. United Kingdom
    • 14.6.1. Total market size of Persistent epithelial defect in the United Kingdom
    • 14.6.2. Market size of Persistent epithelial defect by Therapies in the UK
  • 14.7. Japan
    • 14.7.1. Total market size of Persistent epithelial defect in Japan
    • 14.7.2. Market size of Persistent epithelial defect by Therapies in Japan

15. Market Drivers

16. Market Barriers

17. SWOT Analysis

18. Market Access and Reimbursement

19. Case studies

  • 19.1. Refractory case of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops
  • 19.2. Treatment of Chronic Non-healing Neurotrophic Corneal Epithelial Defects with Thymosin Beta 4
  • 19.3. Healing Persistent Epithelial Defects: A Case Study
  • 19.4. Rapid healing of a persistent corneal epithelial defect (PCED) with autologous serum treatment

20. KOL Views

21. Bibliography

22. Appendix

  • 22.1. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Tables

  • Table 1: Total Incident cases of Persistent epithelial defect in 7MM (2017-2030)
  • Table 2: Total Incident cases of Persistent epithelial defect in the US (2017-2030)
  • Table 3: Etiology-specific cases of Persistent epithelial defect in the US (2017-2030)
  • Table 4: Total Incident cases of Persistent epithelial defect in Germany (2017-2030)
  • Table 5: Etiology-specific cases of Persistent epithelial defect in Germany (2017-2030)
  • Table 6: Total Incident cases of Persistent epithelial defect in France (2017-2030)
  • Table 7: Etiology-specific cases of Persistent epithelial defect in France (2017-2030)
  • Table 8: Total Incident cases of Persistent epithelial defect in Italy (2017-2030)
  • Table 9: Etiology-specific cases of Persistent epithelial defect in Italy (2017-2030)
  • Table 10: Total Incident cases of Persistent epithelial defect in Spain (2017-2030)
  • Table 11: Etiology-specific cases of Persistent epithelial defect in Spain (2017-2030)
  • Table 12: Total Incident cases of Persistent epithelial defect in the UK (2017-2030)
  • Table 13: Etiology-specific cases of Persistent epithelial defect in the UK (2017-2030)
  • Table 14: Total Incident cases of Persistent epithelial defect in Japan (2017-2030)
  • Table 15: Etiology-specific cases of Persistent epithelial defect in Japan (2017-2030)
  • Table 16: Oxervate, Clinical Trial Description, 2020
  • Table 17: Key cross competition
  • Table 18: Nexagon, Clinical Trial Description, 2020
  • Table 19: ST266, Clinical Trial Description, 2020
  • Table 20: RGN-259, Clinical Trial Description, 2020
  • Table 21: REC-0559, Clinical Trial Description, 2020
  • Table 22: DE-105, Clinical Trial Description, 2020
  • Table 23: Market Size of Persistent epithelial defect in 7MM in USD Million (2017-2030)
  • Table 24: Total Market Size of Persistent epithelial defect in the US in USD Million (2017-2030)
  • Table 25: US Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)
  • Table 26: Total Market Size of Persistent epithelial defect in Germany, USD Millions (2017-2030)
  • Table 27: Germany Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)
  • Table 28: Total Market Size of Persistent epithelial defect in France, USD Millions (2017-2030)
  • Table 29: France Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)
  • Table 30: Total Market Size of Persistent epithelial defect in Italy, USD Millions (2017-2030)
  • Table 31: Italy Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)
  • Table 32: Total Market Size of Persistent epithelial defect in Spain, USD Millions (2017-2030)
  • Table 33: Spain Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)
  • Table 34: Total Market Size of Persistent epithelial defect in the UK, USD Millions (2017-2030)
  • Table 35: UK Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)
  • Table 36: Total Market Size of Persistent epithelial defect in Japan, USD Millions (2017-2030)
  • Table 37:Japan Market Size of Persistent epithelial defect by therapies, in USD Million (2017-2030)

List of Figures

  • Figure 1: Epidemiology and Market Methodo+C3:D19logy
  • Figure 2:Depiction of a Persistent Epithelial Defect (PED)
  • Figure 3: Clinical features
  • Table 4: Clinical symptoms and their timely presentation
  • Table 5: Etiologies Of Persistent Corneal Epithelial Defect
  • Figure 6:Normal Epithelial Wound Healing Process
  • Figure 7: Growth Factors and Inflammatory Mediators Involved in the Epithelial Wound Healing Process
  • Figure 8: Total Incident cases of Persistent epithelial defect in 7MM (2017-2030)
  • Figure 9: Total Incident cases of Persistent epithelial defect in the US (2017-2030)
  • Figure 10: Etiology-specific cases of Persistent epithelial defect in the US (2017-2030)
  • Figure 11: Total Incident cases of Persistent epithelial defect in Germany (2017-2030)
  • Figure 12: Etiology-specific cases of Persistent epithelial defect in Germany (2017-2030)
  • Figure 13: Total Incident cases of Persistent epithelial defect in France (2017-2030)
  • Figure 14: Etiology-specific cases of Persistent epithelial defect in France (2017-2030)
  • Figure 15: Total Incident cases of Persistent epithelial defect in Italy (2017-2030)
  • Figure 16: Etiology-specific cases of Persistent epithelial defect in Italy (2017-2030)
  • Figure 17: Total Incident cases of Persistent epithelial defect in Spain (2017-2030)
  • Figure 18: Etiology-specific cases of Persistent epithelial defect in Spain (2017-2030)
  • Figure 19: Total Incident cases of Persistent epithelial defect in the UK (2017-2030)
  • Figure 20: Etiology-specific cases of Persistent epithelial defect in the UK (2017-2030)
  • Figure 21: Total Incident cases of Persistent epithelial defect in Japan (2017-2030)
  • Figure 22: Etiology-specific cases of Persistent epithelial defect in Japan (2017-2030)
  • Table 23: Stepwise Approach for the Management of Persistent Corneal Epithelial Defects
  • Figure 24: Unmet Needs
  • Figure 25: Market Size of Persistent epithelial defect in USD Million (2017-2030)
  • Figure 26: Total Market Size of Persistent epithelial defect in the US, USD Millions (2017-2030)
  • Figure 27: US Market Size of PED by therapies, USD Millions (2017-2030)
  • Figure 28: Total Market Size of Persistent epithelial defect in Germany, USD Millions (2017-2030)
  • Figure 29: Germany, Market Size of PED by therapies, USD Millions (2017-2030)
  • Figure 30: Total Market Size of Persistent epithelial defect in France, USD Millions (2017-2030)
  • Figure 31: France, Market Size of Persistent epithelial defect by therapies, USD Millions (2017-2030)
  • Figure 32:Total Market Size of Persistent epithelial defect in Italy, USD Millions (2017-2030)
  • Figure 33:Italy, Market Size of Persistent epithelial defect by therapies, USD Millions (2017-2030)
  • Figure 34: Total Market Size of Persistent epithelial defect in Spain, USD Millions (2017-2030)
  • Figure 35: Spain, Market Size of Persistent epithelial defect by therapies, USD Millions (2017-2030)
  • Figure 36: Total Market Size of Persistent epithelial defect in the UK, USD Millions (2017-2030)
  • Figure 37: UK, Market Size of Persistent epithelial defect by therapies, USD Millions (2017-2030)
  • Figure 38: Total Market Size of Persistent epithelial defect in Japan, USD Millions (2017-2030)
  • Figure 39: Japan, Market Size of Persistent epithelial defect by therapies, USD Millions (2017-2030)
  • Figure 40: Market Drivers
  • Figure 41:Market Barriers